Linear and branched polymer prodrugs of the water-soluble nucleoside reverse-transcriptase inhibitor emtricitabine as structural materials for long-acting implants.
Journal
Journal of materials chemistry. B
ISSN: 2050-7518
Titre abrégé: J Mater Chem B
Pays: England
ID NLM: 101598493
Informations de publication
Date de publication:
15 06 2022
15 06 2022
Historique:
pubmed:
24
5
2022
medline:
18
6
2022
entrez:
23
5
2022
Statut:
epublish
Résumé
Long-acting drug delivery is a growing area of interest as it overcomes many challenges related to patient adherence to therapy and the pill burden associated with chronic illness. Injectable formulations are becoming more common and drug-releasing implants also provide several opportunities. Highly water soluble drug compounds are poor candidates for long-acting delivery. Here, the water-soluble nucleoside reverse transcriptase inhibitor emtricitabine (FTC) has been used as a novel A-B monomer in step-growth polymerisation with chloroformate functional C
Identifiants
pubmed: 35604111
doi: 10.1039/d2tb00825d
pmc: PMC9199480
doi:
Substances chimiques
Anti-HIV Agents
0
Nucleosides
0
Polymers
0
Prodrugs
0
Reverse Transcriptase Inhibitors
0
Water
059QF0KO0R
DNA-Directed RNA Polymerases
EC 2.7.7.6
Emtricitabine
G70B4ETF4S
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
4395-4404Subventions
Organisme : NIAID NIH HHS
ID : R01 AI134091
Pays : United States
Références
Patient Prefer Adherence. 2012;6:155-64
pubmed: 22399848
Nat Commun. 2018 Jan 22;9(1):315
pubmed: 29358624
J Physiol. 2003 Jan 1;546(Pt 1):307-14
pubmed: 12509498
Pharmaceutics. 2020 Oct 24;12(11):
pubmed: 33114382
Bioengineering (Basel). 2021 Dec 09;8(12):
pubmed: 34940358
AIDS Res Ther. 2021 Nov 2;18(1):81
pubmed: 34727943
Pharm Res. 1993 Mar;10(3):369-80
pubmed: 8464809
Ther Adv Drug Saf. 2013 Apr;4(2):63-71
pubmed: 25083252
Antimicrob Agents Chemother. 2020 Feb 21;64(3):
pubmed: 31871073
Nat Nanotechnol. 2008 Aug;3(8):506-11
pubmed: 18685640
Patient Prefer Adherence. 2021 Aug 24;15:1853-1871
pubmed: 34465984
Cardiol Ther. 2021 Dec;10(2):445-464
pubmed: 34586613
J Int AIDS Soc. 2021 Jun;24(6):e25756
pubmed: 34105865
Nat Commun. 2019 Mar 29;10(1):1413
pubmed: 30926773
J Clin Exp Dent. 2015 Oct 01;7(4):e447-50
pubmed: 26535087
Biomater Sci. 2016 Jan;4(1):9-24
pubmed: 26323327
Arch Dermatol. 2003 Jan;139(1):17-20
pubmed: 12533157
Adv Drug Deliv Rev. 2016 Aug 1;103:144-156
pubmed: 26916628
J Mater Chem B. 2016 Feb 7;4(5):902-909
pubmed: 32263163
Sci Transl Med. 2016 Nov 16;8(365):365ra157
pubmed: 27856796
Macromolecules. 2005;38(16):6895-6901
pubmed: 23976793
Psychopharmacol Bull. 2017 May 15;47(2):42-52
pubmed: 28626271
Antimicrob Agents Chemother. 2016 Apr 22;60(5):2941-8
pubmed: 26926634
Am Fam Physician. 1998 Jun;57(11):2789-98
pubmed: 9636341
J Antimicrob Chemother. 2016 Apr;71(4):856-61
pubmed: 26747092
Nat Commun. 2016 Oct 21;7:13184
pubmed: 27767027
Lancet Glob Health. 2021 May;9(5):e620-e627
pubmed: 33770513
Macromol Rapid Commun. 2009 Jul 1;30(13):1101-8
pubmed: 21706573
J Mater Chem B. 2021 Dec 15;9(48):9874-9884
pubmed: 34870664
Crit Rev Ther Drug Carrier Syst. 2019;36(2):137-181
pubmed: 30806211
Biomaterials. 2000 Dec;21(24):2507-12
pubmed: 11071600
Clin Epidemiol. 2017 Dec 18;10:17-29
pubmed: 29296098
Lancet Infect Dis. 2022 Jan;22(1):26
pubmed: 34953553